Cost-effectiveness of nusinersen for spinal muscular atrophy: Reply

Vinay Prasad

doi:10.1001/jamapediatrics.2018.0733

Cost-effectiveness of nusinersen for spinal muscular atrophy: Reply

Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	701-702
Number of pages	2
Journal	JAMA Pediatrics
Volume	172
Issue number	7
DOIs	https://doi.org/10.1001/jamapediatrics.2018.0733
State	Published - Jul 2018

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1001/jamapediatrics.2018.0733

Cite this

@article{fb3cd28f76ae44b583dc4b6c9577b7ac,

title = "Cost-effectiveness of nusinersen for spinal muscular atrophy: Reply",

author = "Vinay Prasad",

year = "2018",

month = jul,

doi = "10.1001/jamapediatrics.2018.0733",

language = "English (US)",

volume = "172",

pages = "701--702",

journal = "JAMA Pediatrics",

issn = "2168-6203",

publisher = "American Medical Association",

number = "7",

}

TY - JOUR

T1 - Cost-effectiveness of nusinersen for spinal muscular atrophy

T2 - Reply

AU - Prasad, Vinay

PY - 2018/7

Y1 - 2018/7

UR - http://www.scopus.com/inward/record.url?scp=85049505251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049505251&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2018.0733

DO - 10.1001/jamapediatrics.2018.0733

M3 - Letter

AN - SCOPUS:85049505251

SN - 2168-6203

VL - 172

SP - 701

EP - 702

JO - JAMA Pediatrics

JF - JAMA Pediatrics

IS - 7

ER -

Cost-effectiveness of nusinersen for spinal muscular atrophy: Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this